Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vivos Therapeutics, Inc. (VVOS)
USD0.42
+0.01 (+1.42%)
US NASDAQ Healthcare Medical - Devices
Address
7921 Southpark Plaza 80120
Littleton, CO, US
Littleton, CO, US
CEO
R. Kirk Huntsman
Website
vivos.com
IPO
2020-12-11
CIK 1716166 ISIN US92859E2072
Description
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.42
+0.01 (+1.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
6.08
Float Shares
3.19M
Free Float %
54.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.48% | +10.24% | -12.52% | -50.00% | -69.03% | -65.52% | -70.83% | -92.67% | -99.47% | -99.69% | -99.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.42
Low
1.75
+321.2%
Consensus
2.13
+412.6%
Median
2.13
+411.4%
High
2.50
+501.7%
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
2.13
+412.6%
|
| Last Year | 2 |
2.13
+412.6%
|
| All Time | 3 |
2.17
+422.3%
|
Quality scores
Altman Z-Score
-10.17
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+16.1% ★ Q1'26: +70.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+7.2% Q1'26: -15.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-91.1% Q1'26: -116.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-114.1% Q1'26: -128.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-200.5% Q1'26: -297.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+104.7% Q1'26: +70.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.73× Q1'26: -0.50× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
13.07M
est: 12.94M (+1.0%)
|
16.89M
est: 17.30M (-2.4%)
|
16.02M
est: 16.55M (-3.2%)
|
13.80M
est: 14.02M (-1.6%)
|
15.03M
est: 15.20M (-1.1%)
|
17.44M
est: 20.71M (-15.8%)
|
22.98M
21.78M – 25.21M
+11.0% YoY
|
39.52M
36.82M – 42.76M
+72.0% YoY
|
| EBITDA |
-11.24M
est: -11.81M (+4.8%)
|
-19.54M
est: -15.79M (-23.8%)
|
-24.36M
est: -15.10M (-61.3%)
|
-16.68M
est: -13.19M (-26.4%)
|
-10.59M
est: -14.30M (+26.0%)
|
-18.59M
est: -19.49M (+4.6%)
|
-21.62M
-23.72M – -20.49M
-11.0% YoY
|
-37.18M
-40.24M – -34.64M
-72.0% YoY
|
| EBIT |
-11.96M
est: -12.05M (+0.7%)
|
-20.27M
est: -16.11M (-25.8%)
|
-25.03M
est: -15.41M (-62.4%)
|
-17.30M
est: -13.30M (-30.0%)
|
-11.17M
est: -14.42M (+22.5%)
|
-19.89M
est: -19.65M (-1.3%)
|
-21.80M
-23.92M – -20.66M
-11.0% YoY
|
-37.49M
-40.57M – -34.93M
-72.0% YoY
|
| Net Income |
-12.06M
est: -75.30M (+84.0%)
|
-20.29M
est: -112.95M (+82.0%)
|
-23.85M
est: -131.14M (+81.8%)
|
-13.58M
est: -61.24M (+77.8%)
|
-11.14M
est: -20.94M (+46.8%)
|
-21.23M
est: -20.22M (-5.0%)
|
-12.28M
-13.75M – -10.81M
+39.2% YoY
|
-1.81M
-1.99M – -1.64M
+85.2% YoY
|
| SGA |
18.40M
est: 22.03M (-16.5%)
|
31.34M
est: 29.46M (+6.4%)
|
34.38M
est: 28.18M (+22.0%)
|
24.95M
est: 24.63M (+1.3%)
|
19.61M
est: 26.71M (-26.6%)
|
29.13M
est: 36.38M (-19.9%)
|
40.37M
38.26M – 44.30M
+11.0% YoY
|
69.42M
64.68M – 75.12M
+72.0% YoY
|
| EPS |
-24.70
est: -15.00 (-64.7%)
|
-23.89
est: -22.50 (-6.2%)
|
-25.90
est: -26.50 (+2.3%)
|
-11.14
est: -5.91 (-88.6%)
|
-2.22
est: -2.02 (-9.9%)
|
-2.06
est: -1.95 (-5.6%)
|
-1.24
-1.34 – -1.05
+36.4% YoY
|
-0.18
-0.19 – -0.16
+85.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | Ascendiant Capital | Buy | Buy | Maintain |
| 2026-04-17 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-17.00M
OE per share TTM
-1.58
Owner's Yield
-165.93%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
25.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
2.15M
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dave Singh | 3.25M | 14.10% | 30.0K | 3.22M | 30.0K | 3.22M | IN | States | 2022-02-14 | ↗ |
| 2 | LP | 3.22M | 14.00% | 3.22M | — | 3.22M | — | PN | Arizona | 2022-02-14 | ↗ |
| 3 | Kirk Huntsman | 2.21M | 9.62% | 2.21M | — | 2.21M | — | IN | States | 2022-02-14 | ↗ |
| 4 | V Partners, LLC | 1.74M | 7.60% | 1.74M | — | 1.74M | — | OO | Wyoming | 2022-02-14 | ↗ |
| 5 | Brendan O’Neil | 412.1K | 8.70% | — | 412.1K | — | 412.1K | IN | California, United States | 2024-09-24 | ↗ |
| 6 | Ionic Management, LLC | 412.1K | 8.70% | — | 412.1K | — | 412.1K | OO | California, United States | 2024-09-24 | ↗ |
| 7 | Ionic Ventures, LLC | 412.1K | 8.70% | — | 412.1K | — | 412.1K | OO | California, United States | 2024-09-24 | ↗ |
| 8 | Keith Coulston | 412.1K | 8.70% | — | 412.1K | — | 412.1K | IN | California, United States | 2024-09-24 | ↗ |
| 9 | Armistice Capital, LLC | 175.1K | 9.99% | — | 175.1K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 10 | Steven Boyd | 175.1K | 9.99% | — | 175.1K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
+5 vs prev Q
New positions
8
Closed positions
3
Increased
11
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 304.2K +212.7K (+232.6%) | 617.4K +333.9K (+117.8%) | 2.77% +1.768 pp | 0.00% +0.000 pp | USD2.65 -23.4% | 9 qtrs — |
| 2 | DRW SECURITIES, LLC | 115.9K +74.4K (+179.5%) | 235.3K +106.7K (+83.0%) | 1.06% +0.601 pp | 0.01% +0.004 pp | USD2.41 -15.8% | 2 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 56.3K +3.0K (+5.6%) | 114.3K -50.9K (-30.8%) | 0.51% -0.073 pp | 0.00% +0.000 pp | USD2.99 -32.1% | 7 qtrs — |
| 4 | B. RILEY WEALTH ADVISORS, INC. | 43.5K +— (+0.0%) | 88.4K -46.6K (-34.5%) | 0.40% -0.082 pp | 0.00% -0.002 pp | USD3.16 -35.8% | 3 qtrs — |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 40.5K -500.0 (-1.2%) | 82.2K -44.8K (-35.3%) | 0.37% -0.082 pp | 0.00% 0.000 pp | USD3.23 -37.2% | 8 qtrs — |
| 6 | BLACKROCK, INC. | 27.8K +— (+0.0%) | 56.5K -29.8K (-34.5%) | 0.25% -0.052 pp | 0.00% +0.000 pp | USD3.10 -34.5% | 2 qtrs — |
| 7 | STATE STREET CORP | 24.9K +— (+0.0%) | 50.6K -26.7K (-34.5%) | 0.23% -0.047 pp | 0.00% +0.000 pp | USD2.98 -31.9% | 4 qtrs — |
| 8 | ACORN WEALTH ADVISORS, LLC | 14.8K +14.8K (+100.0%) | 30.0K +30.0K (+100.0%) | 0.13% +0.135 pp | 0.01% +0.009 pp | USD2.03 +0.0% | 1 qtrs NEW |
| 9 | UBS GROUP AG | 12.7K +12.6K (+12,328.4%) | 25.7K +25.4K (+8,043.7%) | 0.12% +0.115 pp | 0.00% +0.000 pp | USD2.04 -0.5% | 6 qtrs — |
| 10 | NORTHERN TRUST CORP | 12.5K +— (+0.0%) | 25.4K -13.4K (-34.5%) | 0.11% -0.024 pp | 0.00% +0.000 pp | USD2.85 -28.8% | 4 qtrs — |
| 11 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.0K +171.0 (+6.1%) | 6.0K -2.6K (-30.5%) | 0.03% -0.004 pp | 0.00% 0.000 pp | USD3.05 -33.4% | 9 qtrs — |
| 12 | ADVISOR GROUP HOLDINGS, INC. | 1.1K -5.4K (-82.6%) | 2.3K -18.4K (-88.8%) | 0.01% -0.062 pp | 0.00% +0.000 pp | USD3.08 -34.1% | 7 qtrs — |
| 13 | SIGNATUREFD, LLC | 547.00 +— (+0.0%) | 1.1K -586.0 (-34.6%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD12.44 -83.7% | 9 qtrs — |
| 14 | RONALD BLUE TRUST, INC. | 160.00 +— (+0.0%) | 325.00 -171.0 (-34.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.37 -39.8% | 8 qtrs — |
| 15 | BANK OF AMERICA CORP /DE/ | 132.00 +15.0 (+12.8%) | 267.00 -96.0 (-26.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.07 -33.9% | 8 qtrs — |
| 16 | KOZAK & ASSOCIATES, INC. | 49.00 +— (+0.0%) | 101.00 -16.0 (-13.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD12.43 -83.7% | 9 qtrs — |
| 17 | MORGAN STANLEY | 7.00 -1.1K (-99.3%) | 14.00 -3.3K (-99.6%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD3.29 -38.3% | 9 qtrs — |
| 18 | CITIGROUP INC | 1.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -32.3% | 2 qtrs — |
| 19 | RENAISSANCE TECHNOLOGIES LLC | — -39.3K (-100.0%) | — -121.8K (-100.0%) | 0.00% -0.432 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 20 | FMR LLC | — -40.0 (-100.0%) | — -124.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 21 | GLOBAL RETIREMENT PARTNERS, LLC | — -23.0 (-100.0%) | — -71.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 22 | CONNECTIVE CAPITAL MANAGEMENT, LLC | — -200.0K (-100.0%) | — -620.0K (-100.0%) | 0.00% -2.201 pp | 0.00% -0.569 pp | USD— | 2 qtrs SOLD |
| 23 | STRATEGIC WEALTH INVESTMENT GROUP, LLC | — -100.0K (-100.0%) | — -310.0K (-100.0%) | 0.00% -1.100 pp | 0.00% -0.026 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 41.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 315.31 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 865.73 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 63.95 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 148.1K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 324.11 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 176.60 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 71.19 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 7.90 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.11 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
5.35M
Shares disposed
—
Cash buys
5.00
Cash sales
—
Net activity
+5,350,746
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | V-Co Investors 3 LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,353,625 | D | ↗ |
| 2026-03-31 | Skaff Michael C | 10% Owner | P-Purchase | A | Series B Common Stock Warrant | 1,783,582 | 1.09 | 1.94M | 1,783,582 | I | ↗ |
| 2026-02-04 | JOHNSON GREGG C | Director | — | — | Common Stock | 0 | 0.00 | — | 3,997 | I | ↗ |
| 2025-06-09 | Skaff Michael C | 10% Owner | — | — | Pre-Funded Warrant | 725,258 | 0.00 | 72.53 | 0 | I | ↗ |
| 2024-11-26 | Huntsman Ronald Kirk | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 315,421 | 2.64 | 832.7K | 364,755 | D | ↗ |
| 2024-11-26 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 149,533 | 2.64 | 394.8K | 180,533 | D | ↗ |
| 2024-06-20 | Thompson Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 4,000 | 2.38 | 9.5K | 7,067 | — | ↗ |
| 2024-06-20 | SOKOLOW LEONARD J | Director | A-Award | A | Stock Option (Right to Buy) | 4,000 | 2.38 | 9.5K | 7,467 | — | ↗ |
| 2024-06-20 | Lindsay Mark F. | Director | A-Award | A | Stock Option (Right to Buy) | 4,000 | 2.38 | 9.5K | 7,067 | — | ↗ |
| 2024-06-20 | Krammer Anja B | Director | A-Award | A | Stock Option (Right to Buy) | 4,000 | 2.38 | 9.5K | 7,067 | — | ↗ |
| 2024-06-20 | Huntsman Ronald Kirk | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.38 | 47.6K | 49,334 | — | ↗ |
| 2024-06-20 | Green Ralph Elias | Director | A-Award | A | Stock Option (Right to Buy) | 4,000 | 2.38 | 9.5K | 7,067 | — | ↗ |
| 2024-06-20 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.38 | 35.7K | 31,667 | — | ↗ |
| 2024-06-10 | Skaff Michael C | 10% Owner | — | — | Common Stock Purchase Warrant | 3,220,266 | 2.20 | 7.10M | 0 | I | ↗ |
| 2023-06-20 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 14,000 | 0.53 | 7.4K | 86,521 | — | ↗ |
| 2023-06-16 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.53 | 2.7K | 72,521 | — | ↗ |
| 2023-06-15 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 21 | 0.50 | 10.50 | 57,521 | — | ↗ |
| 2023-06-14 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.49 | 4.9K | 57,500 | — | ↗ |
| 2022-12-23 | Thompson Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.48 | 14.4K | 76,667 | — | ↗ |
| 2022-12-23 | SOKOLOW LEONARD J | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.48 | 14.4K | 76,667 | — | ↗ |
| 2022-12-23 | Lindsay Mark F. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.48 | 14.4K | 76,667 | — | ↗ |
| 2022-12-23 | Krammer Anja B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.48 | 14.4K | 76,667 | — | ↗ |
| 2022-12-23 | Huntsman Ronald Kirk | Officer | P-Purchase | A | Common Stock | 20,000 | 0.50 | 10.0K | 47,500 | — | ↗ |
| 2022-12-23 | Green Ralph Elias | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.48 | 14.4K | 76,667 | — | ↗ |
| 2022-12-23 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.48 | 96.0K | 500,001 | — | ↗ |
| 2022-05-31 | Huntsman Ronald Kirk | Officer | P-Purchase | A | Common Stock | 8,000 | 2.03 | 16.2K | 23,500 | — | ↗ |
| 2022-02-25 | Huntsman Ronald Kirk | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 3.27 | 408.8K | 125,000 | — | ↗ |
| 2022-02-25 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.27 | 163.5K | 50,000 | — | ↗ |
| 2021-09-21 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.31 | 21.6K | 15,500 | — | ↗ |
| 2021-08-31 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.26 | 263.0K | 50,000 | — | ↗ |
| 2021-08-17 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 3.00 | 15.0K | 10,500 | — | ↗ |
| 2021-08-05 | Thompson Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-08-05 | Singh Gurdev Dave | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-08-05 | SOKOLOW LEONARD J | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-08-05 | Lindsay Mark F. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-08-05 | Krammer Anja B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-08-05 | Green Ralph Elias | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.72 | 81.6K | 46,667 | — | ↗ |
| 2021-06-16 | Huntsman Ronald Kirk | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.64 | 705.0K | 125,000 | — | ↗ |
| 2021-05-25 | Huntsman Ronald Kirk | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 5.38 | 21.5K | 5,500 | — | ↗ |
| 2021-05-25 | Amman Bradford K. | Officer | P-Purchase | A | Common Stock | 1,000 | 5.29 | 5.3K | 2,000 | — | ↗ |
| 2021-03-12 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 7.50 | 750.0K | 100,000 | — | ↗ |
| 2020-12-24 | Amman Bradford K. | Officer | P-Purchase | A | Common Stock | 1,000 | 7.38 | 7.4K | 1,000 | — | ↗ |
| 2020-12-23 | Huntsman Ronald Kirk | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 7.27 | 7.3K | 1,500 | — | ↗ |
| 2020-12-11 | Huntsman Ronald Kirk | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 8.50 | 4.3K | 500 | — | ↗ |
| 2020-12-10 | Thompson Matthew | Director | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2020-12-10 | Singh Gurdev Dave | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,219,705 | — | ↗ |
| 2020-12-10 | SOKOLOW LEONARD J | Director | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2020-12-10 | Lindsay Mark F. | Director | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2020-12-10 | Krammer Anja B | Director | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2020-12-10 | Huntsman Ronald Kirk | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,749,000 | — | ↗ |
| 2020-12-10 | Green Ralph Elias | Director | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2020-12-10 | Amman Bradford K. | Officer | — | D | Stock option (Right to buy) | 16,667 | 7.50 | 125.0K | 0 | — | ↗ |
| 2019-11-18 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,667 | 7.50 | 125.0K | 16,667 | — | ↗ |
| 2018-10-22 | Amman Bradford K. | Officer | A-Award | A | Stock Option (Right to Buy) | 83,334 | 7.50 | 625.0K | 83,334 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-189.5K
Shares Outstanding
5.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | R. Kirk Huntsman Chief Executive Officer | 408.7K | — | — | 801.6K | 77.7K | 18.9K | 1.31M | 61.33% | ↗ |
| 2 | 2024 | Bradford Amman Chief Financial Officer | 267.6K | — | — | 390.8K | 26.4K | 22.0K | 705.9K | 55.36% | ↗ |
| 3 | 2023 | R. Kirk Huntsman Chief Executive Officer | 373.5K | — | — | — | — | 18.8K | 567.8K | 0.00% | ↗ |
| 4 | 2023 | Bradford Amman Chief Financial Officer | 253.7K | — | — | — | — | 22.0K | 340.1K | 0.00% | ↗ |
| 5 | 2022 | R. Kirk Huntsman Chief Executive Officer | 384.9K | — | — | 483.8K | 50.6K | 18.5K | 937.9K | 51.59% | ↗ |
| 6 | 2022 | Bradford Amman Chief Financial Officer | 256.5K | — | — | 195.7K | 20.9K | 19.8K | 492.9K | 39.70% | ↗ |
| 7 | 2022 | G. Dave Singh Chief Medical Officer | 73.2K | — | — | — | — | 4.3K | 77.5K | 0.00% | ↗ |
| 8 | 2022 | G. Dave Singh Former Chief Medical Officer | 73.7K | — | — | — | — | 4.3K | 77.5K | 0.00% | ↗ |
| 9 | 2021 | Bradford Amman Chief Financial Officer | 230.2K | — | — | 805.6K | 52.0K | 18.3K | 1.11M | 72.83% | ↗ |
| 10 | 2021 | R. Kirk Huntsman Chief Executive Officer | 344.2K | — | — | 570.3K | 144.3K | 18.3K | 1.08M | 52.95% | ↗ |
| 11 | 2021 | G. Dave Singh Former Chief Medical Officer | 288.3K | — | — | — | 75.7K | 15.9K | 447.0K | 0.00% | ↗ |
| 12 | 2020 | R. Kirk Huntsman , Chief Executive Officer (principal executive officer) | 251.8K | — | — | — | 177.8K | 25.7K | 455.3K | 0.00% | ↗ |
| 13 | 2020 | R. Kirk Huntsman Chief Executive Officer | 251.8K | — | — | — | 177.8K | 25.7K | 455.3K | 0.00% | ↗ |
| 14 | 2020 | G. Dave Singh Chief Medical Officer | 250.5K | — | — | — | 33.0K | 15.0K | 298.5K | 0.00% | ↗ |
| 15 | 2020 | G. Dave Singh Former Chief Medical Officer | 250.5K | — | — | — | 33.0K | 15.0K | 298.5K | 0.00% | ↗ |
| 16 | 2020 | Bradford Amman Chief Financial Officer | 181.2K | — | — | — | 65.3K | 22.4K | 268.9K | 0.00% | ↗ |
| 17 | 2020 | Bradford Amman Chief Financial Officer (principal accounting officer) | 181.2K | — | — | — | 65.3K | 22.4K | 268.9K | 0.00% | ↗ |
| 18 | 2019 | R. Kirk Huntsman , Chief Executive Officer (principal executive officer) | 249.2K | — | — | — | 57.0K | 21.9K | 328.1K | 0.00% | ↗ |
| 19 | 2019 | Bradford Amman Chief Financial Officer (principal accounting officer) | 180.0K | — | — | 98.7K | — | 18.5K | 297.2K | 33.22% | ↗ |
| 20 | 2019 | G. Dave Singh Chief Medical Officer | 249.2K | — | — | — | 28.9K | 16.2K | 294.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| R. Kirk Huntsman | Co-Founder, Chairman of the Board & Chief Executive Officer | 511.1K | male |
| Bradford K. Amman | Chief Financial Officer, Treasurer & Secretary | 357.6K | male |
| John Ballard | Senior Vice President of Technology | — | male |
| Michael E. Bruhn | Executive Vice President of Business Operations Integration | — | male |
| Nicholas DeGennaro | Senior Vice President of Mergers and Acquisition Group | — | male |
| Jennifer Hauser | Executive Assistant to CEO and Chairman & CFO | — | — |
| RaeAnn Byrnes | Co-Founder and Senior Vice President of Events & Clinical Advisory Services | — | female |
| Ruth Hembree | Senior Vice President of Practice Services | — | female |
| Susan McCullough | Co-Founder & Executive Vice President of Operations | — | female |
| Terry Jones | Senior Vice President of Human Resources | — | — |
| Todd Huntsman | Co-Founder & Senior Vice President of Product and Technology | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VVOS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
